Unlocking the Commercial Potential of Psychedelics
PSYCH is a data and insights platform for the psychedelic healthcare industry.
The Psychedelics as Medicine Report: Third Edition
The leading resource for comprehensive insight and
intelligence on the global psychedelics industry.
Follow us on Twitter
🧠Kernel Flow and the need for neuroimaging data
🪖Veterans Affairs studies psychedelic medicines
🍄Colorado activists file psilocybin ballot initiative
Read more in Issue 87 of The Psychedelics Newsletter: https://bit.ly/3nnpCYS
🍏Eating disorders and psychedelic healthcare
⚕️World Health Organization publishes mental health report
💲KPMG evaluates the potential of psychedelic healthcare
Read more in Issue 86 of The Psychedelics Newsletter: https://bit.ly/3QEgMTV
Psilocybin therapy has shown efficacy in patients with treatment-resistant depression, with regulatory approval expected in 2024.
@COMPASSPathway's CEO, George Goldsmith, discussed the Phase IIb clinical trial and the future of psychedelic medicine: $CMPS
PSYCH Webinar - COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evid...
bit.ly
Are we at risk of overstating the capabilities of psychedelic medicine?
At PSYCH Symposium, George Goldsmith, CEO at @COMPASSPathway, discussed industry sustainability with @ProfDavidNutt and @ProfCeliaMorgan from @Awakn_ls: https://bit.ly/3Oy0ydh $CMPS $AWKN
According to the @WHO, in 2020 the number of individuals with anxiety or depression increased by over 25%.
There are now over a billion people with a mental health disorder, 14% of which are adolescents.
Download the World mental health report:
World mental health report: Transforming mental health for all
9789240049338
bit.ly